Evolution of combined modality therapy for stage III non-small-cell lung cancer

David R Gandara, Martin Edelman, Primo N Lara, Derick H Lau, Peter Roberts, Bryan Leigh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A number of randomized clinical trials and meta-analyses now support the conclusion that combined modality regimens that include cisplatin (Platinol)-based chemotherapy improve survival in stage III non-small-cell lung cancer (NSCLC) more effectively than radiotherapy or surgery alone. Depending on the therapy, chemotherapy may play a cytoreductive role by eradicating distant micrometastases, a radiosensitizing role by improving local control, or do both. In general, sequential therapies in which platinum-based chemotherapy precedes thoracic radiation or surgery have improved outcome by affecting distant metastases. In contrast, concurrent chemoradiotherapy utilizing low-dose cisplatin improves survival by reducing local recurrence without an effect on distant failure rates. In view of these observations, chemoradiotherapy strategies that integrate both radiosensitizing agents and dose levels of chemotherapy that are effective against micrometastases may prove to be most efficacious. Since distant metastases remain the major site of failure, it is also likely that more effective chemotherapy or other systemic antitumor agents are necessary to increase the current level of response and survival. Fortunately, several new chemotherapeutic agents are highly effective against NSCLC as well as potent radiosensitizers.

Original languageEnglish (US)
Pages (from-to)35-41
Number of pages7
JournalOncology
Volume14
Issue number7 SUPPL. 5
StatePublished - 2000

Fingerprint

Combined Modality Therapy
Non-Small Cell Lung Carcinoma
Drug Therapy
Cisplatin
Neoplasm Micrometastasis
Chemoradiotherapy
Radiation-Sensitizing Agents
Neoplasm Metastasis
Platinum
Antineoplastic Agents
Meta-Analysis
Radiotherapy
Thorax
Randomized Controlled Trials
Radiation
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Evolution of combined modality therapy for stage III non-small-cell lung cancer. / Gandara, David R; Edelman, Martin; Lara, Primo N; Lau, Derick H; Roberts, Peter; Leigh, Bryan.

In: Oncology, Vol. 14, No. 7 SUPPL. 5, 2000, p. 35-41.

Research output: Contribution to journalArticle

Gandara, DR, Edelman, M, Lara, PN, Lau, DH, Roberts, P & Leigh, B 2000, 'Evolution of combined modality therapy for stage III non-small-cell lung cancer', Oncology, vol. 14, no. 7 SUPPL. 5, pp. 35-41.
Gandara, David R ; Edelman, Martin ; Lara, Primo N ; Lau, Derick H ; Roberts, Peter ; Leigh, Bryan. / Evolution of combined modality therapy for stage III non-small-cell lung cancer. In: Oncology. 2000 ; Vol. 14, No. 7 SUPPL. 5. pp. 35-41.
@article{e2e3193d8cbc4d1e8a648d00d41bd6b5,
title = "Evolution of combined modality therapy for stage III non-small-cell lung cancer",
abstract = "A number of randomized clinical trials and meta-analyses now support the conclusion that combined modality regimens that include cisplatin (Platinol)-based chemotherapy improve survival in stage III non-small-cell lung cancer (NSCLC) more effectively than radiotherapy or surgery alone. Depending on the therapy, chemotherapy may play a cytoreductive role by eradicating distant micrometastases, a radiosensitizing role by improving local control, or do both. In general, sequential therapies in which platinum-based chemotherapy precedes thoracic radiation or surgery have improved outcome by affecting distant metastases. In contrast, concurrent chemoradiotherapy utilizing low-dose cisplatin improves survival by reducing local recurrence without an effect on distant failure rates. In view of these observations, chemoradiotherapy strategies that integrate both radiosensitizing agents and dose levels of chemotherapy that are effective against micrometastases may prove to be most efficacious. Since distant metastases remain the major site of failure, it is also likely that more effective chemotherapy or other systemic antitumor agents are necessary to increase the current level of response and survival. Fortunately, several new chemotherapeutic agents are highly effective against NSCLC as well as potent radiosensitizers.",
author = "Gandara, {David R} and Martin Edelman and Lara, {Primo N} and Lau, {Derick H} and Peter Roberts and Bryan Leigh",
year = "2000",
language = "English (US)",
volume = "14",
pages = "35--41",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "7 SUPPL. 5",

}

TY - JOUR

T1 - Evolution of combined modality therapy for stage III non-small-cell lung cancer

AU - Gandara, David R

AU - Edelman, Martin

AU - Lara, Primo N

AU - Lau, Derick H

AU - Roberts, Peter

AU - Leigh, Bryan

PY - 2000

Y1 - 2000

N2 - A number of randomized clinical trials and meta-analyses now support the conclusion that combined modality regimens that include cisplatin (Platinol)-based chemotherapy improve survival in stage III non-small-cell lung cancer (NSCLC) more effectively than radiotherapy or surgery alone. Depending on the therapy, chemotherapy may play a cytoreductive role by eradicating distant micrometastases, a radiosensitizing role by improving local control, or do both. In general, sequential therapies in which platinum-based chemotherapy precedes thoracic radiation or surgery have improved outcome by affecting distant metastases. In contrast, concurrent chemoradiotherapy utilizing low-dose cisplatin improves survival by reducing local recurrence without an effect on distant failure rates. In view of these observations, chemoradiotherapy strategies that integrate both radiosensitizing agents and dose levels of chemotherapy that are effective against micrometastases may prove to be most efficacious. Since distant metastases remain the major site of failure, it is also likely that more effective chemotherapy or other systemic antitumor agents are necessary to increase the current level of response and survival. Fortunately, several new chemotherapeutic agents are highly effective against NSCLC as well as potent radiosensitizers.

AB - A number of randomized clinical trials and meta-analyses now support the conclusion that combined modality regimens that include cisplatin (Platinol)-based chemotherapy improve survival in stage III non-small-cell lung cancer (NSCLC) more effectively than radiotherapy or surgery alone. Depending on the therapy, chemotherapy may play a cytoreductive role by eradicating distant micrometastases, a radiosensitizing role by improving local control, or do both. In general, sequential therapies in which platinum-based chemotherapy precedes thoracic radiation or surgery have improved outcome by affecting distant metastases. In contrast, concurrent chemoradiotherapy utilizing low-dose cisplatin improves survival by reducing local recurrence without an effect on distant failure rates. In view of these observations, chemoradiotherapy strategies that integrate both radiosensitizing agents and dose levels of chemotherapy that are effective against micrometastases may prove to be most efficacious. Since distant metastases remain the major site of failure, it is also likely that more effective chemotherapy or other systemic antitumor agents are necessary to increase the current level of response and survival. Fortunately, several new chemotherapeutic agents are highly effective against NSCLC as well as potent radiosensitizers.

UR - http://www.scopus.com/inward/record.url?scp=0034220253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034220253&partnerID=8YFLogxK

M3 - Article

C2 - 10981289

AN - SCOPUS:0034220253

VL - 14

SP - 35

EP - 41

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 7 SUPPL. 5

ER -